Ohad Hammer
CIK: 0002116400
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AGMB
Agomab Therapeutics NV
Director
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Hammer Ohad
Hammer Ohad (SEC CIK 0002116400) files insider reports with the SEC as Director of Agomab Therapeutics NV (AGMB).
Signal8 holds 1 ownership filing by Hammer Ohad, a Form 3, filed on Mar 18, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Hammer Ohad's filings is in ANTWERPEN.
Other insiders filing for Agomab Therapeutics NV (AGMB)
- Epstein David R, Director
- Kemula Pierre Thadee Victor, Chief Financial Officer
- Knotnerus Tim Jasper, Chief Executive Officer
- Garcia Marino, Director
- Patel Naimish, Director
- Bond Colin Michael, Director